

### AMENDMENTS TO THE SPECIFICATION

1. Amend the title to read: "HIV env Antibodies".
2. Amend the specification by replacing the first paragraph with the following paragraph:

### CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation of co-pending application(s) Serial No. 08/802,361, filed on February 19, 1997 (now U.S. Patent No. 5,849,533), which is a continuation of Serial No. 08/226,162, filed on April 11, 1994 (now U.S. Patent No. 5,674,984), which is a divisional of Serial No. 08/101,669, filed on August 2, 1993 (now abandoned), which is a continuation of Serial No. 07/834,735, filed on February 13, 1992 (now abandoned), which is a divisional of Serial No. 07/504,785, filed April 3, 1990 (now abandoned), which applications are incorporated herein by reference and to which applications(s) priority is claimed under 35 USC §120.

3. Amend the abstract by replacing the paragraph beginning at line 4 on page 69 with the following paragraph:

~~Unclipped HIV env polypeptides are provided which are not proteolytically cleaved at an internal clip site, along with methods for their preparation and use. Monoclonal antibodies are also provided. The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/gp120 binding and reduce reverse transcriptase activity *in vitro*.~~